Clinical and pathologic characteristics associated with IDH-mutant AML include normal karyotype (intermediate-risk cytogenetics), increased patient age, elevated platelet count, increased bone marrow blast percentage at initial presentation, increased peripheral blast percentage, decreased absolute neutrophil count (especially in IDH1-mutant AML), and concurrent mutations such as NPM1 and FLT3-ITD (44–47, 54). This evidence concerns the gene NPM1 and acute myeloid leukemia.